Tradegate
30.12.25 | 10:09
33,800 Euro
+1,20 % +0,400
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,000 | 30.12.25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus | 3 | Zacks | ||
| 19.12.25 | Castle Biosciences, Inc.: Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 17.12.25 | Castle Biosciences' melanoma test outperforms NGS in eye cancer study | 1 | Investing.com | ||
| 17.12.25 | Castle Biosciences, Inc.: Landmark Study Shows Combination of Castle Biosciences' DecisionDx-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma | 1 | GlobeNewswire (USA) | ||
| 12.12.25 | Castle Biosciences, Inc.: Systematic Review and Meta-Analysis Confirms TissueCypher Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer | 341 | GlobeNewswire (Europe) | FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication... ► Artikel lesen | |
| 09.12.25 | Castle Biosciences, Inc.: Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma | 3 | GlobeNewswire (USA) | ||
| CASTLE BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.11.25 | Castle Biosciences: Starke Wachstumsdynamik und erhöhte Umsatzprognose | 6 | Investing.com Deutsch | ||
| 17.11.25 | Castle Biosciences, Inc.: Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year | 2 | GlobeNewswire (USA) | ||
| 14.11.25 | Castle Biosciences: Melanom-Test verbessert Risikoprognose und stützt Aktienkurs | 2 | Investing.com Deutsch | ||
| 14.11.25 | Castle Biosciences melanoma test shows improved risk prediction | 1 | Investing.com | ||
| 14.11.25 | Castle Biosciences, Inc.: New Data Confirms Performance of DecisionDx-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity | 729 | GlobeNewswire (Europe) | FRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data... ► Artikel lesen | |
| 07.11.25 | SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million | 341 | PR Newswire | STOCKHOLM, Nov. 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that SciBase... ► Artikel lesen | |
| 05.11.25 | Why Castle Biosciences' Rally Might Just Be Getting Started | 3 | Benzinga.com | ||
| 04.11.25 | Castle Biosciences stock price target raised to $38 from $32 at BTIG | 1 | Investing.com | ||
| 04.11.25 | Castle Biosciences Stock Surges 19% After Q3 Results And Guidance Raise | - | RTTNews | ||
| 04.11.25 | Canaccord bestätigt Kaufempfehlung für Castle Biosciences nach starken Q3-Zahlen | 1 | Investing.com Deutsch | ||
| 04.11.25 | Castle Biosciences stock maintains Buy rating at Canaccord on strong Q3 | 1 | Investing.com | ||
| 04.11.25 | Castle Biosciences outlines $33B AdvanceAD-Tx market opportunity while raising 2025 revenue guidance | 1 | Seeking Alpha | ||
| 04.11.25 | Castle Biosciences Q3 2025 slides: test volume surges 36%, revenue beats forecasts | 1 | Investing.com | ||
| 03.11.25 | Castle Biosciences übertrifft im dritten Quartal 2025 die Prognosen: Testvolumen steigt um 36 % | - | Investing.com Deutsch |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 48,980 | +0,60 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,760 | +0,37 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,920 | +0,54 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum ersten Geschäftsquartal auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 40,000 | -1,57 % | EILMELDUNG: Carl Zeiss Meditec-Aktie stabil - Marktbeobachter rechnen mit Bewegung. | ||
| DRAEGERWERK | 69,40 | +0,14 % | EQS-News: Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener Aktien - Abschlussmeldung | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Sonstiges
Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener... ► Artikel lesen | |
| GERRESHEIMER | 27,580 | 0,00 % | Comeback 2026! Verzehnfachung möglich? Evotec, Gerresheimer, Desert Gold Aktie! | Auf der Suche nach einem möglichen Verzehnfacher im Gold-Sektor? Dies halten Analysten bei Desert Gold für möglich. Die jüngste PEA für das Flaggschiff-Gold-Projekt löst neue Kursfantasie aus. Damit... ► Artikel lesen | |
| INTUITIVE SURGICAL | 486,45 | -0,55 % | Where Will Intuitive Surgical Be in 5 Years? | ||
| TELADOC HEALTH | 5,901 | -0,07 % | Teladoc Health, Inc.: Teladoc Health Announces Chief Financial Officer Transition | NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that Mala Murthy will be stepping down from her role as Chief Financial... ► Artikel lesen | |
| ROKU | 93,91 | -0,37 % | Cathie Woods ARK kauft bei Biotech-Werten zu und verkauft Roku-Aktien | ||
| BICO GROUP | 1,925 | -0,93 % | BICO Group AB: Jesper Hagberg appointed as Chief Operations & Digital Officer for BICO Group AB | BICO Group AB today announces the appointment of Jesper Hagberg as Chief Operations & Digital Officer.
Jesper Hagberg brings over 25 years of experience as CIO, CDO and Transformation Leader, driving... ► Artikel lesen | |
| EUROFINS SCIENTIFIC | 62,44 | +0,10 % | Eurofins Scientific SE: Director/PDMR Shareholding | Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each... ► Artikel lesen | |
| DEXCOM | 57,10 | -0,38 % | DexCom, Inc.: Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy | New personalised learning platform aims to build confidence in healthcare professional (HCP) CGM knowledge, no matter their previous experience, and support high-quality diabetes care. ... ► Artikel lesen | |
| ALCON | 68,28 | -0,03 % | Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference | Regulatory News:
Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST.
A live webcast of the conference... ► Artikel lesen | |
| INMODE | 12,525 | -1,07 % | InMode Ltd.: InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins | YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced... ► Artikel lesen | |
| PETMED EXPRESS | 2,853 | -1,14 % | PetMed Express, Inc.: PetMed Express Comments on Unsolicited and Non-Binding Acquisition Proposal Received From SilverCape Investments Limited | DELRAY BEACH, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the "Company" or "PetMeds"), today confirmed that it has... ► Artikel lesen |
Das Unternehmen CASTLE BIOSCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,20 % bei einem Aktienkurs von 33,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CASTLE BIOSCIENCES INC finden Sie auf Wallstreet Online.